Search

Your search keyword '"Cibula, David"' showing total 1,066 results
Start Over Author "Cibula, David"
1,066 results on '"Cibula, David"'

51. Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial – SENTIX

Author

Zapardiel, Ignacio, Kocian, Roman, Köhler, Cristhardt, Klat, Jaroslav, Germanova, Anna, Jacob, Anna, Bajsova, Sylva, Böhmer, Gerd, Lay, Laura, Gil-Ibañez, Blanca, Havelka, Pavel, Kipp, Barbara, Szewczyk, Grzegorz, Toth, Robert, Staringer, Juan Carlos, De Santiago, Javier, Coronado, Pluvio J., Poka, Robert, Laky, Rene, Luyckx, Mathieu, Fastrez, Maxime, Dusek, Ladislav, Hernandez, Alicia, and Cibula, David

Published
2021
Full Text
View/download PDF

52. Survival associated with extent of radical hysterectomy in early-stage cervical cancer: a subanalysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study

Author

Bizzarri, Nicolò, Querleu, Denis, Dostálek, Lukáš, van Lonkhuijzen, Luc R.C.W., Giannarelli, Diana, Lopez, Aldo, Salehi, Sahar, Ayhan, Ali, Kim, Sarah H., Ortiz, David Isla, Klat, Jaroslav, Landoni, Fabio, Pareja, Rene, Manchanda, Ranjit, Kosťun, Jan, Ramirez, Pedro T., Meydanli, Mehmet M., Odetto, Diego, Laky, Rene, Zapardiel, Ignacio, Weinberger, Vit, Dos Reis, Ricardo, Pedone Anchora, Luigi, Amaro, Karina, Akilli, Huseyin, Abu-Rustum, Nadeem R., Salcedo-Hernández, Rosa A., Javůrková, Veronika, Mom, Constantijne H., Scambia, Giovanni, Falconer, Henrik, and Cibula, David

Published
2023
Full Text
View/download PDF

53. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial

Author

Cibula, David, Rob, Lukas, Mallmann, Peter, Knapp, Pawel, Klat, Jaroslav, Chovanec, Josef, Minar, Lubos, Melichar, Bohuslav, Hein, Alexander, Kieszko, Dariusz, Pluta, Marek, Spacek, Jiri, Bartos, Pavel, Wimberger, Pauline, Madry, Radoslaw, Markowska, Janina, Streb, Joanna, Valha, Petr, Hassan, Hariz Iskandar Bin, Pecen, Ladislav, Galluzzi, Lorenzo, Fucikova, Jitka, Hrnciarova, Tereza, Hraska, Marek, Bartunkova, Jirina, and Spisek, Radek

Published
2021
Full Text
View/download PDF

55. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

Author

Concin, Nicole, Creutzberg, Carien L., Vergote, Ignace, Cibula, David, Mirza, Mansoor Raza, Marnitz, Simone, Ledermann, Jonathan A., Bosse, Tjalling, Chargari, Cyrus, Fagotti, Anna, Fotopoulou, Christina, González-Martín, Antonio, Lax, Sigurd F., Lorusso, Domenica, Marth, Christian, Morice, Philippe, Nout, Remi A., O’Donnell, Dearbhaile E., Querleu, Denis, Raspollini, Maria Rosaria, Sehouli, Jalid, Sturdza, Alina E., Taylor, Alexandra, Westermann, Anneke M., Wimberger, Pauline, Colombo, Nicoletta, Planchamp, François, and Matias-Guiu, Xavier

Published
2021
Full Text
View/download PDF

56. Ten years of live surgical broadcast at Charité-MAYO conferences (2010–2019): a systematic evaluation of the surgical outcome

Author

Altmann, Judith, Chekerov, Radoslav, Fotopoulou, Christina, Muallem, Mustafa-Zelal, du Bois, Andreas, Cliby, William, Dowdy, Sean, Podratz, Karl, Lichtenegger, Werner, Camara, Omar, Tunn, Ralf, Cibula, David, Kuemmel, Sherko, Scambia, Giovanni, Vergote, Ignace, Chiantera, Vito, Pietzner, Klaus, Inci, Melisa Guelhan, Chopra, Sascha, Biebl, Matthias, Neymeyer, Joerg, Blohmer, Jens-Uwe, and Sehouli, Jalid

Published
2022
Full Text
View/download PDF

57. Direct mailing of HPV self-sampling kits to women aged 50-65 non-participating in cervical screening in the Czech Republic.

Author

Ngo, Ondřej, Chloupková, Renata, Cibula, David, Sláma, Jiří, Mandelová, Lucie, Hejduk, Karel, Hajdúch, Marián, Minka, Petr, Koudeláková, Vladimíra, Jaworek, Hana, Trnková, Markéta, Vaněk, Peter, Dvořák, Vladimír, Dušek, Ladislav, and Májek, Ondřej

Subjects
PAPILLOMAVIRUS disease diagnosis, CERVIX uteri tumors, WOMEN, RESEARCH funding, EARLY detection of cancer, POSTAL service, DESCRIPTIVE statistics, PAP test, COMPARATIVE studies, CONFIDENCE intervals, GYNECOLOGIC examination, PATIENT self-monitoring
Abstract

Background: A population-based cervical cancer screening programme is implemented in the Czech Republic. However, participation is insufficient among women over 50 years. This study aimed to estimate the potential improvement in participation through directly mailed HPV self-sampling kits (HPVssk) compared with standard invitation letters in women aged 50-65 non-participating in screening. Methods: The study recruited 1564 eligible women (no cervical cancer screening in the last 3 years or more, no previous treatment associated with cervical lesions or cervical cancer). Eight hundred women were mailed with an HPVssk (HPVssk group), and 764 women were sent a standard invitation letter (control group) inviting them to a routine screening (Pap test). The primary outcome was a comparison of the overall participation rate between study groups using a binominal regression model. Results: The participation rate in the HPVssk group was 13.4% [95% confidence interval (CI) 11.2-15.9%; 7.4% of women returned the HPVssk and 6.0% attended gynaecological examination] and 5.0% (95% CI 3.6-6.8%) in the control group. Using the binominal regression model, the difference between the groups was estimated as 7.6% (95% CI 5.0-10.2%; P<0.001). In the HPVssk group, 22% of women who returned HPVssk had a positive result and 70% of them underwent a follow-up examination. Conclusions: Compared with traditional invitation letters, the direct mailing of the HPVssk achieved a significantly higher participation rate, along with a notable HPV positivity rate among HPVssk responders. This approach offers a potentially viable method for engaging women who have not yet attended a cervical screening programme. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

59. Plasma cell‐free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case‐control study and an ovarian cancer screening trial.

Author

Herzog, Chiara, Jones, Allison, Evans, Iona, Reisel, Daniel, Olaitan, Adeola, Doufekas, Konstantinos, MacDonald, Nicola, Rådestad, Angelique Flöter, Gemzell‐Danielsson, Kristina, Zikan, Michal, Cibula, David, Dostálek, Lukáš, Paprotka, Tobias, Leimbach, Andreas, Schmitt, Markus, Ryan, Andy, Gentry‐Maharaj, Aleksandra, Apostolidou, Sophia, Rosenthal, Adam N, and Menon, Usha

Subjects
CELL-free DNA, OVARIAN cancer, DNA methylation, DNA analysis, EARLY detection of cancer, CIRCULATING tumor DNA, CASE-control method
Abstract

Analysis of cell‐free DNA methylation (cfDNAme), alone or combined with CA125, could help to detect ovarian cancers earlier and may reduce mortality. We assessed cfDNAme in regions of ZNF154, C2CD4D and WNT6 via targeted bisulfite sequencing in diagnostic and early detection (preceding diagnosis) settings. Diagnostic samples were obtained via prospective blood collection in cell‐free DNA tubes in a convenience series of patients with a pelvic mass. Early detection samples were matched case‐control samples derived from the UK Familial Ovarian Cancer Screening Study (UKFOCSS). In the diagnostic set (ncases = 27, ncontrols = 41), the specificity of cfDNAme was 97.6% (95% CI: 87.1%‐99.9%). High‐risk cancers were detected with a sensitivity of 80% (56.3%‐94.3%). Combination of cfDNAme and CA125 resulted in a sensitivity of 94.4% (72.7%‐99.9%) for high‐risk cancers. Despite technical issues in the early detection set (ncases = 29, ncontrols = 29), the specificity of cfDNAme was 100% (88.1%‐100.0%). We detected 27.3% (6.0%‐61.0%) of high‐risk cases with relatively lower genomic DNA (gDNA) contamination. The sensitivity rose to 33.3% (7.5%‐70.1%) in samples taken <1 year before diagnosis. We detected ovarian cancer in several patients up to 1 year before diagnosis despite technical limitations associated with archival samples (UKFOCSS). Combined cfDNAme and CA125 assessment may improve ovarian cancer screening in high‐risk populations, but future large‐scale prospective studies will be required to validate current findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

61. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial

Author

Pignata, Sandro, Oza, Amit, Hall, Geoff, Pardo, Beatriz, Madry, Radoslaw, Cibula, David, Klat, Jaroslav, Montes Worboys, Ana, Glasspool, Rosalind, Colombo, Nicoletta, Pete, Imre, Herrero Ibáñez, Ana, Romeo Marín, Margarita, Ilieva, Rumyana, Timcheva, Constanta, Maio, Massimo di, Blakeley, Christopher, Taylor, Rosie, Barnicle, Alan, Clamp, Andrew, Pignata, S, Oza, A, Hall, G, Pardo, B, Madry, R, Cibula, D, Klat, J, Montes, A, Glasspool, R, Colombo, N, Pete, I, Herrero Ibáñez, A, Marín, M, Ilieva, R, Timcheva, C, Di Maio, M, Blakeley, C, Taylor, R, Barnicle, A, and Clamp, A

Subjects
Olaparib, Oncology, Maintenance, Ovarian cancer, BRCA mutation, Càncer d'ovari, Genetics, Obstetrics and Gynecology, HRR, Genètica
Abstract

Background: The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) who had tumor BRCA mutations (BRCAm) of germline (g) or somatic (s) origin or non-BRCA homologous recombination repair mutations (HRRm) and were in response to their most recent platinum-based chemotherapy after ≥2 lines of treatment. Methods: Patients received maintenance olaparib capsules (400mg twice daily) until disease progression. Prospective central testing at screening determined tumor BRCAm status and subsequent testing determined gBRCAm or sBRCAm status. Patients with predefined non-BRCA HRRm were assigned to an exploratory cohort. The co-primary endpoints were investigator-assessed progression-free survival (PFS; modified Response Evaluation Criteria in Solid Tumors v1.1) in BRCAm and sBRCAm cohorts. Secondary endpoints included health-related quality of life (HRQoL) and tolerability. Results: 177 patients received olaparib. At the primary data cut-off (17 April 2020), the median follow-up for PFS in the BRCAm cohort was 22.3months. The median PFS (95% CI) in BRCAm, sBRCAm, gBRCAm and non-BRCA HRRm cohorts was 18.0 (14.3-22.1), 16.6 (12.4-22.2), 19.3 (14.3-27.6) and 16.4 (10.9-19.3) months, respectively. Most patients with BRCAm reported improvements (21.8%) or no change (68.7%) in HRQoL and the safety profile was as expected. Conclusions: Maintenance olaparib had similar clinical activity in PSR OC patients with sBRCAm and those with any BRCAm. Activity was also observed in patients with a non-BRCA HRRm. ORZORA further supports use of maintenance olaparib in all patients with BRCA-mutated, including sBRCA-mutated, PSR OC.

Published
2023

64. SUCCOR cone study: conization before radical hysterectomy

Author

Chacon, Enrique, Manzour, Nabil, Zanagnolo, Vanna, Querleu, Denis, Núñez-Córdoba, Jorge M, Martin-Calvo, Nerea, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Shamistan, Aliyev, Moreno, Antonio Gil, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Castellanos, Teresa, Boria, Felix, Alcazar, Juan Luis, and Chiva, Luis

Published
2022
Full Text
View/download PDF

65. Pathologic Protocols for Sentinel Lymph Nodes Ultrastaging in Cervical Cancer

Author

Dundr, Pavel, Cibula, David, Nemejcova, Kristyna, Ticha, Ivana, Bartu, Michaela, and Jaksa, Radek

Subjects
Cervical cancer, Health
Abstract

Context.--Ultrastaging of sentinel lymph nodes (SLNs) is a crucial aspect in the approach to SLN processing. No consensual protocol for pathologic ultrastaging has been approved by international societies to date. Objective.--To provide a review of the ultrastaging protocol and all its aspects related to the processing of SLNs in patients with cervical cancer. Data Sources.--In total, 127 publications reporting data from 9085 cases were identified in the literature. In 24% of studies, the information about SLN processing is entirely missing. No ultrastaging protocol was used in 7% of publications. When described, the differences in all aspects of SLN processing among the studies and institutions are substantial. This includes grossing of the SLN, which is not completely sliced and processed in almost 20% of studies. The reported protocols varied in all aspects of SLN processing, including the thickness of slices (range, 1-5 mm), the number of levels (range, 0-cut out until no tissue left), distance between the levels (range, 40-1000 im), and number of sections per level (range, 1-5). Conclusions.--We found substantial differences in protocols used for SLN pathologic ultrastaging, which can impact sensitivity for detection of micrometastases and even small macrometastases. Since the involvement of pelvic lymph nodes is the most important negative prognostic factor, such profound discrepancies influence the referral of patients to adjuvant radiotherapy and could potentially cause treatment failure. It is urgent that international societies agree on a consensual protocol before SLN biopsy without pelvic lymphadenectomy is introduced into routine clinical practice. doi: 10.5858/arpa.2019-0249-RA, During the last few years, sentinel lymph node (SLN) biopsy has emerged as one of the most promising and effective approaches for patients with early-stage cervical cancer. (1-3) According to [...]

Published
2020
Full Text
View/download PDF

66. Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Author

Grisham, Rachel N., primary, Vergote, Ignace, primary, Banerjee, Susana, primary, Drill, Esther, primary, Kalbacher, Elsa, primary, Mirza, Mansoor Raza, primary, Romero, Ignacio, primary, Vuylsteke, Peter, primary, Coleman, Robert L., primary, Hilpert, Felix, primary, Oza, Amit M., primary, Westermann, Anneke, primary, Oehler, Martin K., primary, Pignata, Sandro, primary, Aghajanian, Carol, primary, Colombo, Nicoletta, primary, Cibula, David, primary, Moore, Kathleen N., primary, del Campo, Josep M., primary, Berger, Regina, primary, Marth, Christian, primary, Sehouli, Jalid, primary, O'Malley, David M., primary, Churruca, Cristina, primary, Kristensen, Gunnar, primary, Clamp, Andrew, primary, Farley, John, primary, Iyer, Gopa, primary, Ray-Coquard, Isabelle, primary, and Monk, Bradley J., primary

Published
2023
Full Text
View/download PDF

67. Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Author

Grisham, Rachel N., primary, Vergote, Ignace, primary, Banerjee, Susana, primary, Drill, Esther, primary, Kalbacher, Elsa, primary, Mirza, Mansoor Raza, primary, Romero, Ignacio, primary, Vuylsteke, Peter, primary, Coleman, Robert L., primary, Hilpert, Felix, primary, Oza, Amit M., primary, Westermann, Anneke, primary, Oehler, Martin K., primary, Pignata, Sandro, primary, Aghajanian, Carol, primary, Colombo, Nicoletta, primary, Cibula, David, primary, Moore, Kathleen N., primary, del Campo, Josep M., primary, Berger, Regina, primary, Marth, Christian, primary, Sehouli, Jalid, primary, O'Malley, David M., primary, Churruca, Cristina, primary, Kristensen, Gunnar, primary, Clamp, Andrew, primary, Farley, John, primary, Iyer, Gopa, primary, Ray-Coquard, Isabelle, primary, and Monk, Bradley J., primary

Published
2023
Full Text
View/download PDF

69. #1119 Survival associated with extent of radical hysterectomy in early-stage cervical cancer: a sub-analysis of the SCCAN collaborative study

Author

Bizzarri, Nicolò, primary, Querleu, Denis, additional, Dostalek, Lukas, additional, Lonkhuijzen, Luc Rcw Van, additional, Giannarelli, Diana, additional, Lopez, Aldo, additional, Salehi, Sahar, additional, Ayhan, Ali, additional, Kim, Sarah K, additional, Ortiz, David Isla, additional, Klat, Jaroslav, additional, Landoni, Fabio, additional, Pareja, Rene, additional, Manchanda, Ranjit, additional, Kostun, Jan, additional, Ramirez, Pedro T, additional, Meydanli, Mehmet M, additional, Odetto, Diego, additional, Laky, Rene, additional, Zapardiel, Ignacio, additional, Weinberger, Vit, additional, Reis, Ricardo Dos, additional, Anchora, Luigi Pedone, additional, Amaro, Karina, additional, Akilli, Huseyin, additional, Abu-Rustum, Nadeem R, additional, Salcedo-Hernandez, Rosa A, additional, Javurkova, Veronica, additional, Mom, Constantijne H, additional, Scambia, Giovanni, additional, Falconer, Henrik, additional, and Cibula, David, additional

Published
2023
Full Text
View/download PDF

70. #84 Trial in progress: a phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer (EC) who responded to chemotherapy (ENGOT-En21 and GOG-3089)

Author

Concin, Nicole, primary, Giorgi, Ugo De, additional, Gorp, Toon Van, additional, Alexandre, Jérôme, additional, Lindemann, Kristina, additional, Marth, Christian, additional, Berger, Regina, additional, Cibula, David, additional, Quindós, María, additional, Bologna, Alessandra, additional, Korach, Jacob, additional, Papadimitriou, Christos, additional, Nicum, Shibani, additional, Collins, Dearbhaile, additional, Myers, Reg, additional, Rothbaum, Wayne, additional, Herzog, Thomas J, additional, Monk, Bradley J, additional, and Cloven, Noelle Gillette, additional

Published
2023
Full Text
View/download PDF

71. #451 Magnetic resonance imaging or expert ultrasound in preoperative local staging of patients with early-stage cervical cancer: final results of the SENTIX prospective, single-arm, international trial (CEEGOG CX-01; ENGOT-CX2)

Author

Kocián, Roman, primary, Siegler, Kathrin, additional, Klát, Jaroslav, additional, Benešová, Klára, additional, Paderno, Mariachiara, additional, Lonkhuijzen, Luc Van, additional, Chaloupková, Barbora, additional, Pilka, Radovan, additional, Michal, Martin, additional, Kašcák, Peter, additional, Kridelka, Frédéric, additional, Pakiž, Maja, additional, Snyman, Leon Cornelius, additional, Barahona, Marc, additional, Sawicki, Sambor, additional, Blecharz, Pawel, additional, Redecha, Mikuláš, additional, Tóth, Róbert, additional, Cibula, David, additional, and Köhler, Christhardt, additional

Published
2023
Full Text
View/download PDF

73. #630 Lower-limb lymphedema after sentinel lymph node biopsy in cervical cancer patients: final results of the SENTIX prospective international study (CEEGOG CX-01/ENGOT-Cx2)

Author

Köhler, Christhardt, primary, Cibula, David, additional, Romanova, Martina, additional, Borcinova, Martina, additional, Meo, Maria Letizia Di, additional, Lonkhuijzen, Lus Van, additional, Laky, Rene, additional, Baydo, Sergey, additional, Zorrero, Cristina, additional, Luyckx, Mathieu, additional, Misiek, Marcin, additional, Coronado, Pluvio J, additional, Fastrez, Maxime, additional, Szewczyk, Grzegorz, additional, Kipp, Barbara, additional, Tingulstad, Soveig, additional, Santiago, Javier De, additional, Poka, Robert, additional, Plaikner, Andrea, additional, and Kocian, Roman, additional

Published
2023
Full Text
View/download PDF

74. #385 Patient satisfaction with ultrasound, CT and WB-DWI/MRI for preoperative ovarian cancer staging: a multicenter prospective survey

Author

Pinto, Patrícia, primary, Borcinova, Martina, additional, Wiesnerova, Markéta, additional, Fruhauf, Filip, additional, Burgetova, Andrea, additional, Masek, Martin, additional, Lambert, Lukas, additional, Chiappa, Valentina, additional, Franchi, Dorella, additional, Testa, Antonia C, additional, Moro, Francesca, additional, Avesani, Giacomo, additional, Panico, Camilla, additional, Alessi, Sarah, additional, Pricolo, Paola, additional, Vigorito, Rafaella, additional, Calareso, Giuseppina, additional, Kocian, Roman, additional, Slama, Jiri, additional, Fagotti, Anna, additional, Urbinati, Ailyn Vidal, additional, Signorelli, Mauro, additional, Valentin, Lil, additional, Cibula, David, additional, and Fischerova, Daniela, additional

Published
2023
Full Text
View/download PDF

75. #743 Observer-reality agreement in assessing ovarian cancer spread and predicting non-resectability in ovarian cancer (ISAAC study, imaging study on advanced ovarian cancer)

Author

Fischerova, Daniela, primary, Pesta, Michal, additional, Blasko, Miroslav, additional, Moruzzi, Maria Cristina, additional, Hundarova, Kristina, additional, Scovazzi, Umberto, additional, Sousa, Natacha, additional, Ambrosio, Marco, additional, Testa, Antonia Carla, additional, Franchi, Dorella, additional, Chiappa, Valentina, additional, Alcazar, Juan Luis, additional, Pinto, Ana Patricia, additional, and Cibula, David, additional

Published
2023
Full Text
View/download PDF

76. #265 ENGOT-EN20/GOG-3083/XPORT-EC-042 a phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma

Author

Vergote, Ignace, primary, Mirza, Mansoor Raza, additional, Coleman, Robert J, additional, Pérez-Fidalgo, Jose Alejandro, additional, Monk, Bradley J, additional, Valabrega, Giorgio, additional, Slomovitz, Brian M, additional, Gorp, Toon Van, additional, Moore, Kathleen, additional, Sehouli, Jalid, additional, Cibula, David, additional, Levy, Tally, additional, Aravantinos, Gerassimos, additional, Li, Kai, additional, Kalyanapu, Pratheek, additional, and Makker, Vicky, additional

Published
2023
Full Text
View/download PDF

77. #829 Imaging in gynecological disease: clinical and ultrasound characteristics of benign retroperitoneal pelvic nerve sheath tumors

Author

Fischerová, Daniela, primary, Sousa, Natacha Quintal De, additional, Santos, Gino, additional, Wong, Lufee, additional, Yulzari, Vered, additional, Bennett, Rosalie, additional, Dundr, Pavel, additional, Burgetova, Andrea, additional, Barsa, Pavel, additional, Gabor, Szabo, additional, Scovazzi, Umberto, additional, and Cibula, David, additional

Published
2023
Full Text
View/download PDF

78. #259 AGO-OVAR 28/ENGOT-Ov57: niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (a multicentre randomised phase III trial)

Author

Heitz, Florian, primary, Petru, Edgar, additional, Henry, Stéphanie, additional, Reuss, Alexander, additional, Cibula, David, additional, Gaba, Lydia, additional, Colombo, Nicoletta, additional, Polleis, Sandra, additional, and Harter, Philipp, additional

Published
2023
Full Text
View/download PDF

80. #556 Reproductive outcomes after fertility-sparing surgery for cervical cancer – results of the fertiss study

Author

Slama, Jiri, primary, Runnebaum, Ingo, additional, Scambia, Giovanni, additional, Fite, Martina Angeles, additional, Bahrehmand, Kiarash, additional, Kommoss, Stefan, additional, Narducci, Fabrice, additional, Matylevich, Olga, additional, Holly, Jessica, additional, Martinelli, Fabio, additional, Koual, Meriem, additional, Samokhvalova, Olena, additional, El-Balat, Ahmed, additional, Corrado, Giacomo, additional, Capîlna, Mihai Emil, additional, Schröder, Willibald, additional, Novàk, Zoltán, additional, Shushkevich, Alexander, additional, Fricova, Lenka, additional, and Cibula, David, additional

Published
2023
Full Text
View/download PDF

81. MILACC study: could undetected lymph node micrometastases have impacted recurrence rate in the LACC trial?

Author

Nitecki, Roni, primary, Ramirez, Pedro T, additional, Dundr, Pavel, additional, Nemejcova, Kristyna, additional, Ribeiro, Reitan, additional, Vieira Gomes, Mariano Tamura, additional, Schmidt, Ronaldo Luis, additional, Bedoya, Lucio, additional, Isla, David Ortiz, additional, Pareja, Rene, additional, Rendón Pereira, Gabriel Jaime, additional, Lopez, Aldo, additional, Kushner, David, additional, and Cibula, David, additional

Published
2023
Full Text
View/download PDF

82. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Author

Vergote, Ignace, primary, Van Nieuwenhuysen, Els, additional, O'Cearbhaill, Roisin E., additional, Westermann, Anneke, additional, Lorusso, Domenica, additional, Ghamande, Sharad, additional, Collins, Dearbhaile C., additional, Banerjee, Susana, additional, Mathews, Cara A., additional, Gennigens, Christine, additional, Cibula, David, additional, Tewari, Krishnansu S., additional, Madsen, Kristine, additional, Köse, Fatih, additional, Jackson, Amanda L., additional, Boere, Ingrid A., additional, Scambia, Giovanni, additional, Randall, Leslie M., additional, Sadozye, Azmat, additional, Baurain, Jean-François, additional, Gort, Eelke, additional, Zikán, Michal, additional, Denys, Hannelore G., additional, Ottevanger, Nelleke, additional, Forget, Frédéric, additional, Mondrup Andreassen, Camilla, additional, Eaton, Lamar, additional, Chisamore, Michael J., additional, Viana Nicacio, Leonardo, additional, Soumaoro, Ibrahima, additional, and Monk, Bradley J., additional

Published
2023
Full Text
View/download PDF

83. Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Author

Grisham, Rachel N., primary, Vergote, Ignace, additional, Banerjee, Susana, additional, Drill, Esther, additional, Kalbacher, Elsa, additional, Mirza, Mansoor Raza, additional, Romero, Ignacio, additional, Vuylsteke, Peter, additional, Coleman, Robert L., additional, Hilpert, Felix, additional, Oza, Amit M., additional, Westermann, Anneke, additional, Oehler, Martin K., additional, Pignata, Sandro, additional, Aghajanian, Carol, additional, Colombo, Nicoletta, additional, Cibula, David, additional, Moore, Kathleen N., additional, del Campo, Josep M., additional, Berger, Regina, additional, Marth, Christian, additional, Sehouli, Jalid, additional, O'Malley, David M., additional, Churruca, Cristina, additional, Kristensen, Gunnar, additional, Clamp, Andrew, additional, Farley, John, additional, Iyer, Gopa, additional, Ray-Coquard, Isabelle, additional, and Monk, Bradley J., additional

Published
2023
Full Text
View/download PDF

84. Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study

Author

Slama, Jiri, Runnebaum, Ingo Bernard, Scambia, Giovanni, Angeles, Martina Aida, Bahrehmand, Kiarash, Kommoss, Stefan, Fagotti, Anna, Narducci, Fabrice, Matylevich, Olga, Holly, Jessica, Martinelli, Fabio, Koual, Meriem, Kopetskyi, Viacheslav, El-Balat, Ahmed, Corrado, Giacomo, Căpîlna, Mihai Emil, Schröder, Willibald, Novàk, Zoltán, Shushkevich, Alexander, Fricová, Lenka, and Cibula, David

Published
2023
Full Text
View/download PDF

88. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?

Author

Vergote, Ignace, ray coquard, isabelle, Lorusso, Domenica, OAKNIN, ANA, Cibula, David, Van Gorp, Toon, Institut Català de la Salut, [Vergote I, Van Gorp T] Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium, Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium, European Union. [Ray-Coquard I] Medical Oncology Department, Centre Léon Bérard and University Claude Bernard Lyon 1, GINECO, Lyon, France. [Lorusso D] Gynecologic Oncology Unit, Catholic University of Sacred Heart and Fondazione Policlinico Gemelli IRCCS, Rome, Italy. [Oaknin A] Gynecologic Cancer Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Cibula D] Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Central and Eastern European Gynecologic Oncology Group (CEEGOG), Prague, Czech Republic, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Pharmacology, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados [COMPUESTOS QUÍMICOS Y DROGAS], Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates [CHEMICALS AND DRUGS], General Medicine, Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Uterine Cervical Neoplasms [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Coll uterí - Càncer - Tractament, Farmàcia - Investigació, Pharmaceutical Preparations::Drugs, Investigational [CHEMICALS AND DRUGS], preparados farmacéuticos::fármacos en investigación [COMPUESTOS QUÍMICOS Y DROGAS], Pharmacology (medical), Immunoglobulines, neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias del cuello uterino [ENFERMEDADES]
Abstract

Recurrent cervical cancer; Combination therapy; Immunotherapy Cáncer cervical recurrente; Terapia de combinación; Inmunoterapia Càncer cervical recurrent; Teràpia combinada; Immunoteràpia Introduction: Recurrent or primary advanced metastatic cervical cancer (R/M CC) has a poor prognosis with a 5-year-survival rate of 16.5%, demanding novel and improved therapies for the treatment of these patients. The first-line standard of care for R/M CC now benefits from the addition of the immune checkpoint inhibitor, pembrolizumab, to platinum-based chemotherapy with paclitaxel and bevacizumab. Additionally, new options for second-line treatment have become available in recent years. Areas covered: Here, we review current investigational drugs and discuss their relative targets, efficacies, and potential within the R/M CC treatment landscape. This review will focus on recently published data and key ongoing clinical trials in patients with R/M CC, covering multiple modes of action, including immunotherapies, antibody-drug conjugates, and tyrosine kinase inhibitors. We searched clinicaltrials.gov for ongoing trials and pubmed.ncbi.nih.gov for recently published trial data, as well as recent years' proceedings from the annual conferences of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Society of Gynaecological Oncology (ESGO), and the International Gynecologic Cancer Society (IGCS). Expert opinion: Therapeutics currently attracting attention include novel immune checkpoint inhibitors, therapeutic vaccinations, antibody-drug conjugates, such as tisotumab vedotin, tyrosine kinase inhibitors targeting HER2, and multitarget synergistic combinations.

Published
2023

90. Response to: Correspondence on 'ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors' by Thomassin-Nagarra et al

Author

Timmerman, Dirk, Cibula, David, Planchamp, François, Bourne, Tom, Landolfo, Chiara, Testa, Antonia Carla, du Bois, Andreas, Chiva, Luis, Concin, Nicole, fisherova, Daniela, Froyman, Wouter, Lemley, Birthe, Loft, Annika, Mereu, Liliana, Morice, Philippe, Querleu, Denis, Vergote, Ignace, Vandecaveye, Vincent, Scambia, Giovanni, and Fotopoulou, Christina

Published
2021
Full Text
View/download PDF

91. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Author

Musacchio, Lucia, Salutari, Vanda, Pignata, Sandro, Braicu, Elena, Cibula, David, Colombo, Nicoletta, Frenel, Jean Sebastien, Zagouri, Flora, Carbone, Vittoria, Ghizzoni, Viola, Giolitto, Serena, Giudice, Elena, Perri, Maria Teresa, Ricci, Caterina, Scambia, Giovanni, and Lorusso, Domenica

Published
2021
Full Text
View/download PDF

92. Determining post-operative morbidity and mortality following gynecological oncology surgery: protocol for a multicenter, international, prospective cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative—GO SOAR)

Author

Gaba, Faiza, Bizzarri, Nicolò, Kamfwa, Paul, Saiz, Allison, Blyuss, Oleg, Paranjothy, Shantini, Ramirez, Pedro T, Cibula, David, Elshami, Mohamedraed, Saad, Mahmoud, Nafea, Ahmed, Elhadi, Muhammed, Ismail, Alaa, Al-Naggar, Hamza, Cecilia, Darin Maria, Lanner, Maximilian, Pletnev, Andrei, Refky, Basel, Elkady, Abdelazez, Karkour, Tarek, Ali, Hazim Salah, Ghozy, Sherief, Daghash, Sameh, Elmelegy, Mohamed Hamed, Monier, Eman, Mohammad, Mohammad Abdel-Rahman, Ferraioli, Domenico, Nikolova, Tanja, Petousis, Stamatios, Theofanakis, Charalampos, Mishra, Jagannth, Annapurna, Vadaparty, Ifthikar, Mariam Anjum, Ghosh, Anik, Vallabhaneni, Ajay Chanakya, Kar, Bijoy, Al-khafaji, Alyaa, Al-Isawi, Ali, O’Leary, Michael, Martinelli, Fabio, Arcieri, Martina, Restaino, Stefano, Fagotti, Anna, Cola, Edoardo, Bogliolo, Stefano, Shatnawi, Qais, Zazo, Aya, Sindiani, Amer Mahmoud, Alsardieh, Wafa, Qasem, Abdulrahman, Husain, Shatha, Kamarudin, Maherah, Korch, Moniba, Lawal, Ishak, Okunowo, Adeyemi, Alkronz, Mohammed, Lago, Victor, Alsattari, Amani, Abuzaina, Khalil, Shahin, Farah, Aljuba, Ayat, Hatab, Waleed Abu, Salameh, Najib, Radi, Adnan, Casanova, João, Zalewski, Kamil, Yousif, Amel, Govorov, Igor, Abu-Zaid, Ahmed, Alghamdi, Susan, Moreno, Antonio Gil, Rodriguez, Natalia, Boria, Felix, Razumova, Zoia, Alshehabi, Zuheir, Hassan, Bassam, Nawfal, Hamdi, Hamza, Amr, Aker, Seda Şahin, Taskin, Salih, Kahramanoglu, Ilker, Selcuk, Ilker, Gurumurthy, Mahalakshmi, Cairns, Mary, McPherson, Lori, Ghaem-Maghami, Sadaf, Butler, John, Ang, Christine, Sharma, Aarti, Al-Naggar, Hamza, Saif, Sara, Abualdahab, Noor, Qaderi, Shohra, Fundafunda, Swali V, Awad, Mohammed, Karout, Lina, Kassab, Mohamad B, Safar, Ali, Abdallah, Reem, Hatoum, Sana, Elmakkaoui, Said Mohamad, Itani, Rania, El Hassan, Jihad, Karout, Samar, Edine, Hussein Mansour Jamal, Atallah, David, Kacimi, Salah Eddine Oussama, Mohamed, Mustafa, Tan, Chee Yang, Haidar, Hanan, Shehada, Wafaa, Abou-Taleb, Hisham Ahmed, Herdan, Mohamed O., Ali, Ali Hussien, Ahmed, Ahmed Ragab Ali, Mohamed, Omar Salah Ibrahim, Omar, Mohamed I, Zineldin, Eman Ibrahim, El-hamouly, Ahmed Sabry Fouad, Hajjaj, Baraa N., Yousef, Shukri Odeh, Shaheen, Besan, Elhossini, Akram, Obiedat, Ziena, Alsumadi, Maen, Ahmed, Bisan, Abed, Salsabeel, Husaini, Akram, Abusharkh, Subhi Maher, and Angeles, Martina Aida

Published
2021
Full Text
View/download PDF

93. Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators

Author

Boria, Felix, Chiva, Luis, Zanagnolo, Vanna, Querleu, Denis, Martin-Calvo, Nerea, Căpîlna, Mihai Emil, Fagotti, Anna, Kucukmetin, Ali, Mom, Constantijne, Chakalova, Galina, Shamistan, Aliyev, Malzoni, Mario, Narducci, Fabrice, Arencibia, Octavio, Raspagliesi, Francesco, Toptas, Tayfun, Cibula, David, Kaidarova, Dilyara, Meydanli, Mehmet Mutlu, Tavares, Mariana, Golub, Dmytro, Perrone, Anna Myriam, Poka, Robert, Tsolakidis, Dimitrios, Vujić, Goran, Jedryka, Marcin A, Zusterzeel, Petra L M, Beltman, Jogchum Jan, Goffin, Frederic, Haidopoulos, Dimitrios, Haller, Herman, Jach, Robert, Yezhova, Iryna, Berlev, Igor, Bernardino, Margarida, Bharathan, Rasiah, Lanner, Maximilian, Maenpaa, Minna M, Sukhin, Vladyslav, Feron, Jean-Guillaume, Fruscio, Robert, Kukk, Kersti, Ponce, Jordi, Alonso-Espías, María, Minguez, Jose Angel, Vázquez-Vicente, Daniel, Manzour, Nabil, Jurado, Matias, Castellanos, Teresa, Chacon, Enrique, and Alcazar, Juan Luis

Published
2021
Full Text
View/download PDF

95. The genetic landscape of 87 ovarian germ cell tumors

Author

Van Nieuwenhuysen, Els, Busschaert, Pieter, Neven, Patrick, Han, Sileny N., Moerman, Philippe, Liontos, Michalis, Papaspirou, Maria, Kupryjanczyk, Jolanta, Hogdall, Claus, Hogdall, Estrid, Oaknin, Ana, Garcia, Angel, Mahner, Sven, Trillsch, Fabian, Cibula, David, Heitz, Florian, Concin, Nicole, Speiser, Paul, Salvesen, Helga, Sehouli, Jalid, Lambrechts, Diether, and Vergote, Ignace

Published
2018
Full Text
View/download PDF

96. Sonographic, Demographic, and Clinical Characteristics of Pre- and Postmenopausal Women with Endometrial Cancer; Results from a Post Hoc Analysis of the IETA4 (International Endometrial Tumor Analysis) Multicenter Cohort.

Author

Green, Rasmus W., Fischerová, Daniela, Testa, Antonia C., Franchi, Dorella, Frühauf, Filip, Lindqvist, Pelle G., di Legge, Alessia, Cibula, David, Fruscio, Robert, Haak, Lucia A., Opolskiene, Gina, Vidal Urbinati, Ailyn M., Timmerman, Dirk, Bourne, Tom, van den Bosch, Thierry, and Epstein, Elisabeth

Subjects
ENDOMETRIAL cancer, ENDOMETRIAL tumors, POSTMENOPAUSE, ENDOMETRIAL hyperplasia, CANCER patients, UTERINE hemorrhage, FAMILY history (Medicine)
Abstract

In this study, we conducted a comparative analysis of demographic, histopathological, and sonographic characteristics between pre- and postmenopausal women diagnosed with endometrial cancer, while also examining sonographic and anthropometric features in 'low' and 'intermediate/high-risk' cases, stratified by menopausal status. Our analysis, based on data from the International Endometrial Tumor Analysis (IETA) 4 cohort comprising 1538 women (161 premenopausal, 1377 postmenopausal) with biopsy-confirmed endometrial cancer, revealed that premenopausal women, compared to their postmenopausal counterparts, exhibited lower parity (median 1, IQR 0–2 vs. 1, IQR 1–2, p = 0.001), a higher family history of colon cancer (16% vs. 7%, p = 0.001), and smaller waist circumferences (median 92 cm, IQR 82–108 cm vs. 98 cm, IQR 87–112 cm, p = 0.002). Premenopausal women more often had a regular endometrial–myometrial border (39% vs. 23%, p < 0.001), a visible endometrial midline (23% vs. 11%, p < 0.001), and undefined tumor (73% vs. 84%, p = 0.001). Notably, despite experiencing a longer duration of abnormal uterine bleeding (median 5 months, IQR 3–12 vs. 3 months, 2–6, p < 0.001), premenopausal women more often had 'low' risk disease (78% vs. 46%, p < 0.001). Among sonographic and anthropometric features, only an irregular endometrial–myometrial border was associated with 'intermediate/high' risk in premenopausal women. Conversely, in postmenopausal women, multiple features correlated with 'intermediate/high' risk disease. Our findings emphasize the importance of considering menopausal status when evaluating sonographic features in women with endometrial cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

97. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.

Author

Vergote, Ignace, Pérez-Fidalgo, Jose Alejandro, Hamilton, Erika Paige, Valabrega, Giorgio, Van Gorp, Toon, Sehouli, Jalid, Cibula, David, Levy, Tally, Welch, Stephen, Richardson, Debra L., Guerra, Eva M., Scambia, Giovanni, Henry, Stéphanie, Wimberger, Pauline, Miller, David S., Klat, Jaroslav, Martínez-Garcia, Jerónimo, Raspagliesi, Francesco, Pothuri, Bhavana, and Romero, Ignacio

Published
2023
Full Text
View/download PDF

98. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

Author

Timmerman, Dirk, Planchamp, François, Bourne, Tom, Landolfo, Chiara, du Bois, Andreas, Chiva, Luis, Cibula, David, Concin, Nicole, Fischerova, Daniela, Froyman, Wouter, Madueño, Guillermo Gallardo, Lemley, Birthe, Loft, Annika, Mereu, Liliana, Morice, Philippe, Querleu, Denis, Testa, Antonia Carla, Vergote, Ignace, Vandecaveye, Vincent, Scambia, Giovanni, and Fotopoulou, Christina

Published
2021
Full Text
View/download PDF

99. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023

Author

Cibula, David, primary, Rosaria Raspollini, Maria, additional, Planchamp, François, additional, Centeno, Carlos, additional, Chargari, Cyrus, additional, Felix, Ana, additional, Fischerová, Daniela, additional, Jahnn-Kuch, Daniela, additional, Joly, Florence, additional, Kohler, Christhardt, additional, Lax, Sigurd, additional, Lorusso, Domenica, additional, Mahantshetty, Umesh, additional, Mathevet, Patrice, additional, Raj Naik, Mr, additional, Nout, Remi A, additional, Oaknin, Ana, additional, Peccatori, Fedro, additional, Persson, Jan, additional, Querleu, Denis, additional, Rubio Bernabé, Sandra, additional, Schmid, Maximilian P., additional, Stepanyan, Artem, additional, Svintsitskyi, Valentyn, additional, Tamussino, Karl, additional, Zapardiel, Ignacio, additional, and Lindegaard, Jacob Christian, additional

Published
2023
Full Text
View/download PDF

100. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Author

Mirza, Mansoor R., primary, Chase, Dana M., additional, Slomovitz, Brian M., additional, dePont Christensen, René, additional, Novák, Zoltán, additional, Black, Destin, additional, Gilbert, Lucy, additional, Sharma, Sudarshan, additional, Valabrega, Giorgio, additional, Landrum, Lisa M., additional, Hanker, Lars C., additional, Stuckey, Ashley, additional, Boere, Ingrid, additional, Gold, Michael A., additional, Auranen, Annika, additional, Pothuri, Bhavana, additional, Cibula, David, additional, McCourt, Carolyn, additional, Raspagliesi, Francesco, additional, Shahin, Mark S., additional, Gill, Sarah E., additional, Monk, Bradley J., additional, Buscema, Joseph, additional, Herzog, Thomas J., additional, Copeland, Larry J., additional, Tian, Min, additional, He, Zangdong, additional, Stevens, Shadi, additional, Zografos, Eleftherios, additional, Coleman, Robert L., additional, and Powell, Matthew A., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results